Itaconate potentiates hepatic gluconeogenesis through NRF2 induction
PLOS One · 2025
DOI: 10.1371/journal.pone.0322946 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Marwa O El-Derany und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan, United States of America. Hauptthemen laut MEDLINE: Gluconeogenesis, NF-E2-Related Factor 2, Succinates, Liver. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NCI NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
The interplay between systemic metabolism and immune responses is increasingly recognized as a significant factor in the dysregulation of glucose homeostasis associated with diabetes and obesity. Immune metabolites play crucial roles in mediating this crosstalk, with itaconate emerging as an important immune metabolite involved in the inflammatory response of macrophages. Recent studies have highlighted the role of itaconate as a regulator of glucose metabolism, particularly in the context of obesity, although the underlying mechanisms remain poorly understood. In this study, we identified itaconate as one of the metabolites that significantly increase in the liver during fasting compared to fed conditions. Mechanistically, we found that itaconate enhances glucagon-induced liver gluconeogenesis independently of insulin signaling. Notably, itaconate upregulates the expression of gluconeogenic genes both under basal conditions and in the presence of palmitic acid. Furthermore, our data indicate that the effects of itaconate occur independently of CREB activation. Instead, we demonstrate that these potentiating effects are mediated through the induction of nuclear factor erythroid 2-related factor 2 (NRF2). Our findings demonstrate that itaconate has a glucagon-potentiating effects in the liver, suggesting that itaconate may play a significant role in the pathogenesis of metabolic-associated liver diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan, United States of America.
- Department of Biochemistry, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
- University of Michigan Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, United States of America.
- Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States of America.
ORCID-Profile: Yatrik M Shah
Förderung
- NIDDK NIH HHS
- NCI NIH HHS
- NINDS NIH HHS
Zitieren
APA
El-Derany, M. O., Ramakrishnan, S. K., Li, Y., Buscher, K., Jarad, C. A., Schaller, M. L., Cantwell, M., Vigil, T. M., Frieler, R. A., Sajjakulnukit, P., Lyssiotis, C. A., Mortensen, R. M., & Shah, Y. M. (2025). Itaconate potentiates hepatic gluconeogenesis through NRF2 induction. PLOS One. https://doi.org/10.1371/journal.pone.0322946
Vancouver
El-Derany MO, Ramakrishnan SK, Li Y, Buscher K, Jarad CA, Schaller ML, et al. Itaconate potentiates hepatic gluconeogenesis through NRF2 induction. PLOS One. 2025. doi:10.1371/journal.pone.0322946
BibTeX
@article{ElDerany2025,
author = {El-Derany, Marwa O and Ramakrishnan, Sadeesh K and Li, Yingjie and Buscher, Kathryn and Jarad, Christina A and Schaller, Megan L and Cantwell, Marc and Vigil, Thomas M and Frieler, Ryan A and Sajjakulnukit, Peter and Lyssiotis, Costas A and Mortensen, Richard M and Shah, Yatrik M},
title = {Itaconate potentiates hepatic gluconeogenesis through NRF2 induction},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0322946}
}
EUVIMED